EA201992630A1 - METHODS FOR TREATING EYE DISEASES BY APLNR ANTAGONISTS AND VEGF INHIBITORS - Google Patents

METHODS FOR TREATING EYE DISEASES BY APLNR ANTAGONISTS AND VEGF INHIBITORS

Info

Publication number
EA201992630A1
EA201992630A1 EA201992630A EA201992630A EA201992630A1 EA 201992630 A1 EA201992630 A1 EA 201992630A1 EA 201992630 A EA201992630 A EA 201992630A EA 201992630 A EA201992630 A EA 201992630A EA 201992630 A1 EA201992630 A1 EA 201992630A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
eye diseases
aplnr
vegf inhibitors
treating eye
Prior art date
Application number
EA201992630A
Other languages
Russian (ru)
Inventor
Цзинтай Цао
Юнис Чеунг
Иван Б. Лобов
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201992630A1 publication Critical patent/EA201992630A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение представляет способы лечения, профилактики или снижения тяжести заболевания глаз. Способы по данному описанию включают в себя введение субъекту, нуждающемуся в этом, терапевтической композиции, содержащей антагонист APLNR, такой как анти-APLNR антитело, в сочетании с антагонистом фактора роста эндотелия сосудов (VEGF) (например, афлиберцепт).The invention provides methods of treating, preventing, or reducing the severity of an eye disease. The methods described herein include administering to a subject in need thereof a therapeutic composition comprising an APLNR antagonist, such as an anti-APLNR antibody, in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).

EA201992630A 2017-05-06 2018-05-04 METHODS FOR TREATING EYE DISEASES BY APLNR ANTAGONISTS AND VEGF INHIBITORS EA201992630A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502621P 2017-05-06 2017-05-06
PCT/US2018/031255 WO2018208625A1 (en) 2017-05-06 2018-05-04 Methods of treating eye disorders with aplnr antagonists and vegf inhibitors

Publications (1)

Publication Number Publication Date
EA201992630A1 true EA201992630A1 (en) 2020-04-29

Family

ID=62555166

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992630A EA201992630A1 (en) 2017-05-06 2018-05-04 METHODS FOR TREATING EYE DISEASES BY APLNR ANTAGONISTS AND VEGF INHIBITORS

Country Status (10)

Country Link
EP (1) EP3618876A1 (en)
JP (1) JP7161494B2 (en)
KR (1) KR102667021B1 (en)
CN (1) CN110709104A (en)
AU (1) AU2018266324B2 (en)
CA (1) CA3062418A1 (en)
EA (1) EA201992630A1 (en)
IL (1) IL270267B2 (en)
MX (1) MX2019012985A (en)
WO (1) WO2018208625A1 (en)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (en) 1986-10-15 1995-05-24 株式会社大協精工 Stacked syringe stopper
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
JP3100727B2 (en) 1992-01-23 2000-10-23 株式会社大協精工 Modified polysiloxane composition and sanitary rubber product coated with the composition
JP3172057B2 (en) 1995-04-05 2001-06-04 株式会社大協精工 Laminated rubber stopper
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3512349B2 (en) 1999-01-29 2004-03-29 株式会社大協精工 Mold for columnar rubber element
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (en) 2001-01-19 2002-07-30 Daikyo Seiko Ltd Laminated rubber stopper for medical vial
ATE471722T1 (en) 2003-03-12 2010-07-15 Univ Arizona State METHOD FOR REGULATING ANGIOGENESIS USING APELIN COMPOSITIONS
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
CN101478949A (en) 2006-06-16 2009-07-08 瑞泽恩制药公司 VEGF antagonist formulations suitable for intravitreal administration
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma High Affinity Human Antibodies to Human Angiopoietin-2
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
WO2013112438A1 (en) 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
WO2013153049A1 (en) 2012-04-11 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides as apelin inhibitors and uses thereof
JP5775851B2 (en) 2012-06-27 2015-09-09 東京エレクトロン株式会社 Coating apparatus and coating liquid filling method
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
KR20150127596A (en) * 2013-03-14 2015-11-17 리제너론 파아마슈티컬스, 인크. Apelin fusion proteins and uses thereof
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
AU2015233370A1 (en) 2014-03-20 2016-09-22 Centre National De La Recherche Scientifique (Cnrs) Use of compounds inhibiting Apelin / APJ / GP130 signaling for treating cancer
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
JP6959912B2 (en) * 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド Optimized variant of anti-VEGF antibody

Also Published As

Publication number Publication date
AU2018266324A1 (en) 2019-11-28
EP3618876A1 (en) 2020-03-11
IL270267A (en) 2019-12-31
IL270267B1 (en) 2024-02-01
MX2019012985A (en) 2020-01-13
CA3062418A1 (en) 2018-11-15
JP7161494B2 (en) 2022-10-26
KR102667021B1 (en) 2024-05-21
CN110709104A (en) 2020-01-17
KR20200004366A (en) 2020-01-13
WO2018208625A1 (en) 2018-11-15
IL270267B2 (en) 2024-06-01
JP2020518641A (en) 2020-06-25
AU2018266324B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
EA201791168A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR EYE DISEASES
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
UA118029C2 (en) Human fcrn-binding modified antibodies and methods of use
EA201792047A1 (en) NEW CONNECTIONS
EA202190661A1 (en) PHARNESOID X-RECEPTOR AGONISTS FOR DISEASE TREATMENT
EA201500364A1 (en) TREATMENT OF EYE DISEASES
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
UA118453C2 (en) Modulation of tumor immunity
EA201691516A1 (en) DIHYDROPYRROLOPIRIDINOVYY INHIBITORS ROR-GAMMA
EA201690633A1 (en) METHODS AND COMPOSITIONS INCLUDING THE COMBINATION OF ANTAGONIST VEGF AND ANTI-CTLA-4 ANTIBODIES
EA201791227A1 (en) DOSING MODE OF MAdCAM ANTAGONISTS
MX2019001021A (en) Liposome formulations.
EA201592203A1 (en) METHODS OF TREATMENT OF Taupathy
EA201890747A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
EA201991511A1 (en) GREMLIN-1 CRYSTAL STRUCTURE AND AN INHIBITING ANTIBODY
EA201692402A1 (en) MEDICAL FORMS FOR LOCAL APPLICATION AND THEIR USE
EA201891342A1 (en) Isoindole compounds
EA202091221A1 (en) METHOD FOR TREATMENT OR PREVENTION OF IDIOPATIC POLYPOID CHORIOIDAL VASCULOPATHY (IPHV)
CY1121933T1 (en) SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHILIC ELASTASIS ACTIVITY
EA202190094A1 (en) ANTIBODIES AGAINST CD40 FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE
EA201790590A1 (en) HUMANIZED MONOCLONAL ANTIBODY, INHIBITING ENZYMATIVE ACTIVITY OF VASCULAR AND ENDOTHELIAL LIPASE
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
EA201990988A1 (en) ANTIBODIES AGAINST CHIKV AND WAYS OF THEIR APPLICATION
EA202192400A1 (en) ANTIBODIES AGAINST INTEGRIN AND THEIR USE